Clinical Trials Directory

Trials / Unknown

UnknownNCT05761587

Validation of a Screening Scale for Misuse of Opioid Analgesics

Validation of a Screening Scale for the Misuse of Opioid Analgesics in Patients With Chronic Pain Related to Cancer.

Status
Unknown
Phase
Study type
Observational
Enrollment
150 (estimated)
Sponsor
University Hospital, Clermont-Ferrand · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In oncology, pain is one of the main symptoms of discomfort. It has a significant impact on the quality of life.The use of opioid analgesics is recommended for the treatment of moderate to severe cancer pain.The misuse of opioid analgesics is an international public health problem.Different scales have been developed to help the prescriber screen for the risk of misuse in the general population. Patients with cancer-related pain are also at risk for aberrant opioid-related behaviors, misuse or addiction. The main objectif of this study is to validate of the screening scale for the misuse of opioid analgesics in patients with chronic pain related to cancer. (Prescription Opioid Misuse Index - POMI).

Detailed description

The study takes place in 2 phases. Test phase : Questionnaire no. 1 constitutes the data for the TEST phase: it includes socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Concise Pain Questionnaire (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education. Retest phase : questionnaire no. 2 10 to 15 days later.

Conditions

Interventions

TypeNameDescription
OTHERQuestionnairesquestionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.

Timeline

Start date
2023-02-23
Primary completion
2024-04-01
Completion
2025-04-01
First posted
2023-03-09
Last updated
2023-07-18

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT05761587. Inclusion in this directory is not an endorsement.